Patient demographics and clinical data
| Arthralgia | Rheumatoid arthritis | |||
|---|---|---|---|---|
| DAS28<2.6 | 2.6≥DAS28≤5.1 | DAS28>5.1 | ||
| Patients (number) | 10 | 20 | 26 | 13 |
| Age (year) | 39±8 | 48±15 | 59±8 | 57±12 |
| Female (%) | 100 | 70 | 58 | 54 |
| Duration of arthralgia (year) | 3 (1–15) | – | – | – |
| Duration of RA (year) | – | 3 (2–4) | 9 (3–17) | 1 (0–6) |
| ACPA positivity (%) | 0 | 65 | 77 | 69 |
| DAS28 | 3.2±0.9 | 1.7±0.4 | 3.8±0.8 | 5.9±0.6 |
| ESR (mm 1st hour) | 9 (5–13) | 6 (3–10) | 14 (8–24) | 37 (21–55) |
| Raynaud's phenomenon (%) | 0 | 0 | 11 | 15 |
| Use of β-blockers (%) | 0 | 5 | 23 | 0 |
| Use of calcium channel blockers (%) | 0 | 15 | 0 | 0 |
Numbers are presented as mean±SD or median (IQR) unless mentioned otherwise.
Mean of the two physical examiners. Examined joints: shoulders, elbows, wrists, MCP and (P)IP joints of hands and knees.
ACPA, anti-citrullinated protein antibody; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; MCP, metacarpophalangeal; RA, rheumatoid arthritis.